Prostate Cancer Foundation meets the 20 Standards for Charity Accountability.
The Prostate Cancer Foundation (PCF) funds global research programs that encourage collaboration to speed up breakthroughs in prevention, early detection, and genomic medicines for prostate cancer. PCF reports that it provides peer-review research funding to research projects, supporting 2333 scientists at more than 255 cancer centers and universities in 22 countries. The organization's Young Investigator Award program awards funding to early career scientists working in a research environment capable of supporting high-impact prostate cancer research. PCF reports that it also educates the public about prostate cancer, its complications, and standard-of-care research information.
For the year ended December 31, 2019, Prostate Cancer Foundation's program expenses were:
Research grants |
$29,207,005 |
Public awareness |
$6,175,741 |
Scientific conferences and programs |
$4,463,046 |
Total Program Expenses: |
$39,845,792 |
-
Chief Executive
Jonathan Simons, M.D., Chief Executive Officer and President
-
Compensation*
$1,338,610
-
Chair of the Board
Michael Milken
-
Chair's Profession / Business Affiliation
Founder and Chairman, Prostate Cancer Foundation
-
Board Size
28
-
Paid Staff Size
37
*2019 compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
Method(s) Used:
Direct mail appeals, Grant proposals, Internet, Invitations to fund raising events, Planned giving arrangements, Radio, Cause- related marketing (affinity credit cards, consumer product sales, etc.), Television
Prostate Cancer Foundation incurred joint costs of $1,949,853 for informational materials and activities that included fund raising materials. Of those costs $1,120,530 was allocated to program expenses, $789,630 was allocated to fund raising expenses, and $39,693 was allocated to administrative expenses.
Fundraising costs were 11% of related contributions. (Related contributions, which totaled $45,217,305, are donations received as a result of fundraising activities.)
This organization is tax-exempt under section 501(c) (3) of the Internal Revenue Code.It is eligible to receive contributions deductible as charitable donations for federal income tax purposes.
The following information is based on Prostate Cancer Foundation's audited financial statements - consolidated for the year ended December 31, 2019.
Source of Funds |
Grants and contributions |
$45,217,305 |
Interest and dividends |
$190,896 |
Other loss |
($688,762) |
Total Income |
$44,719,439 |
- Programs: 83%
- Fundraising: 10%
- Administrative: 7%
Total Income |
$44,719,439 |
Program expenses |
$39,845,792 |
Fundraising expenses |
$4,773,593 |
Administrative expenses |
$3,714,893 |
Other expenses |
$0 |
Total expenses: |
$48,334,278 |
Income in Excess of Expenses |
$-3,614,839 |
Beginning Net Assets |
$25,262,245 |
Other Changes In Net Assets |
$0 |
Ending Net Assets |
$21,647,406 |
Total Liabilities |
$24,622,162 |
Total Assets |
$46,269,568 |